Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
28 June 2027FDA action dateSelinexorPDUFA date for the XPOVIO plus ruxolitinib sNDA in myelofibrosis
31 August 2026Filing submittedSelinexor (Xpovio)Karyopharm submits an sNDA to FDA for XPOVIO plus ruxolitinib in myelofibrosis (accelerated approval, Priority Review requested)
30 July 2026Topline resultSelinexor (Xpovio)Phase 3 XPORT-EC-042 (NCT05611931) of selinexor maintenance in endometrial cancer did not meet its PFS primary endpoint
Antengene Corporation Limited reported revenue of $12.8M, cash and equivalents of $123.34M, and a net loss of $44.43M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text
Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share prices are end-of-day closes, delayed by 24 hours.